Back to Search Start Over

Pharming Group enrols first patient in Phase III leniolisib clinical trial

Source :
M2 Pharma. February 22, 2023
Publication Year :
2023

Abstract

M2 PHARMA-February 22, 2023-Pharming Group enrols first patient in Phase III leniolisib clinical trial (C)2023 M2 COMMUNICATIONS Pharming Group NV (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR), a Netherlands-based global biopharmaceutical company, [...]

Subjects

Subjects :
Euronext Amsterdam N.V. -- Product development
Pharming Group N.V. -- Product development
Biological products industry -- Product development
Medical research
Medicine, Experimental
B cells
Clinical trials
Securities industry -- Product development
Securities industry
Chemistry

Details

Language :
English
Database :
Gale General OneFile
Journal :
M2 Pharma
Publication Type :
News
Accession number :
edsgcl.738126251

Tools

Authors Abstract Subjects Details